Table 4.
Patient outcome according to mutually adjusted levels of plasma IGF-I and IGFBP-3
Quartile of plasma biomarker |
P for trend* | ||||
---|---|---|---|---|---|
1 | 2 | 3 | 4 | ||
Overall mortality | |||||
IGF-I | |||||
HR for death* (95% CI) | 1.0 (reference) | 0.83 (0.62-1.12) | 0.59 (0.42-0.84) | 0.67 (0.44-1.00) | 0.12 |
IGFBP-3 | |||||
HR for death* (95% CI) | 1.0 (reference) | 0.90 (0.68-1.20) | 0.72 (0.52-0.99) | 0.77 (0.52-1.13) | 0.07 |
Tumor progression | |||||
IGF-I | |||||
HR for tumor progression* (95% CI) | 1.0 (reference) | 0.95 (0.70-1.29) | 0.77 (0.54-1.09) | 1.03 (0.69-1.55) | 0.95 |
IGFBP-3 | |||||
HR for tumor progression* (95% CI) | 1.0 (reference) | 0.80 (0.60-1.07) | 0.66 (0.48-0.91) | 0.60 (0.46-1.01) | 0.03 |
Abbreviation: HR, hazard ratio.
Multivariate hazard ratios, confidence intervals, and P values adjusted for age, gender, performance status, body mass index, treatment arm, and either plasma IGF-I or IGFBP-3 levels.